E
OCUL icon

Ergoteles’s Ocular Therapeutix OCUL Stock Holding History

Ergoteles’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,145
Closed -$106K – 1368
2023
Q1 		$106K Sell
20,145
-43,031
-68% -$204K ﹤0.01% 1096
2022
Q4 		$178K Sell
63,176
-56,089
-47% -$186K 0.01% 1111
2022
Q3 		$495K Buy
+119,265
New +$601K 0.02% 764
2022
Q2 		– Sell
-16,945
Closed -$84K – 1896
2022
Q1 		$84K Sell
16,945
-24,596
-59% -$136K ﹤0.01% 1137
2021
Q4 		$290K Buy
41,541
+5,434
+15% +$42.2K 0.01% 867
2021
Q3 		$361K Buy
+36,107
New +$406K 0.01% 719
2021
Q2 		– Sell
-51,726
Closed -$849K – 1632
2021
Q1 		$849K Buy
+51,726
New +$996K 0.03% 403

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ergoteles's OCUL Position: Q2 2023 in Review

Ergoteles sold out of Ocular Therapeutix (OCUL) in Q2 2023, closing a stake of 20,145 shares — an estimated $106K sold.

Ergoteles first reported a position in OCUL in Q1 2021 and held it in 7 quarters. The position peaked at $849K in Q1 2021. 135 funds tracked by Wall St. Rank hold OCUL as of Q2 2023.

  • Ergoteles reported no remaining Ocular Therapeutix position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 20,145 Ocular Therapeutix shares in Q2 2023, an estimated $106K.
  • Ergoteles first reported a position in Ocular Therapeutix in Q1 2021 and held it in 7 quarters.
  • Ergoteles's Ocular Therapeutix position peaked at $849K in Q1 2021.
  • 135 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.